Dr. Brentjens on the Side Effects of CAR-Modified T Cells

Video

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the side effects of chimeric antigen receptor (CAR)–modified T cells when used to treat B-cell malignancies.

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the side effects of chimeric antigen receptor(CAR)—modified T cells when used to treat B-cell malignancies.

Brentjens says that only patients with a significant amount of disease in their bone marrow developed fevers, low blood pressure, and high heart rate.

The symptoms are likely caused by cytokines, Brentjens says, which are hormones that are secreted by the T cells. When the T cells are infused into the patient, they go into the marrow, recognize the tumor cells, and become activated. Once T cells are activated, they secrete cytokines, Brentjens says.

Brentjens says patients with a large amount of tumor cells require more T cells to activate, resulting in more cytokine secretion. Patients that only have a slight amount of disease left will not have high cytokine levels, and thus, no side effects.

Brentjens says this correlation has led doctors to treat patients with CAR-modified T cells only when they have the minimal amount of disease.

Recent Videos
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
William Chou, MD, on Targeting Progranulin With Gene Therapy for Frontotemporal Dementia
Alexandra Collin de l’Hortet, PhD, the head of therapeutics at Epic Bio
David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI
Joshua M. Hare, MD, on Working to Address Unmet Needs in Alzheimer Disease With Lomecel-B Cell Therapy
John Finn, PhD, the chief scientific officer of Tome Biosciences
David Dimmock, MBBS, on a Promising Case Study of Ultra-Rare, AI-Guided, ASO Development
William Chou, MD, on Expanding Frontotemporal Dementia Gene Therapy to Both GRN and C9orf72 Mutations
Scott Jeffers, PhD, on The Importance of Precise Reproducibility of AAVs
© 2024 MJH Life Sciences

All rights reserved.